Health Care

A new cataract surgery drug gets a quiet agreement

A white box with the drug's name, Dexycu, on the front.
Dexycu has a $595 list price. Photo: EyePoint Pharmaceuticals

A new agreement between a small drugmaker and Kaiser Permanente will allow for the use of a new, pricey cataract surgery drug in Kaiser facilities, except there's one major issue: Nobody's admitting Kaiser is the distributing system.

Why it matters: When it comes to transparency, the health care industry is a black box — even on seemingly small things.

ERs often drop the ball after treating suicidal patients

Emergency rooms don't do a very good job coordinating longer-term care for patients who have attempted suicide — increasing the risk that those patients will try again.

By the numbers: In California, the suicide rate for patients who had been admitted to the ER in the past year for suicidal ideation was a full 57% higher, according to a new study.